Pharmacolog and Codonics extend exclusive U.S. and Canadian distributor agreement to include DrugLog™ in addition to WasteLog®
In December 2020, Pharmacolog and Codonics entered into a distribution agreement, appointing Codonics as the exclusive distributor of WasteLog® in the U.S. and Canadian markets. The agreement is now expanded to include DrugLog™ in both markets. DrugLog™ is a robust and proven stand-alone solution for reducing errors in the drug administration process. In a few seconds, it can verify the identity and concentration of liquid pharmaceuticals in an instant, directly before they’re given to patients, enhancing work efficiency and increasing medication safety.
D
rugLog™ has undergone U.S market approval and was recently registered as a Medical Device with the U.S. Food and Drug Administration (FDA).
“Codonics has the market expertise and existing customer base to successfully introduce DrugLog™ to the American market. Since we started our WasteLog® relationship with Codonics, they have worked purposefully to launch the product in the North American market. We are seeing the results, with a prominent hospital chain in California ordering four units. It is our privilege to expand our agreement to also include DrugLog™,” stated Mats Högberg, CEO, Pharmacalog.
“We are excited to offer DrugLog™ as a complementary offering to the WasteLog® assay device. These products fit with Codonics mission to improve safety. As the exclusive distributor for Pharmacolog, these products will empower us to help hospitals improve diversion control and internal compounding quality control methods”, said Mike Kolberg, Codonics VP Sales. “DrugLog™ provides immediate results and leverages the same superior spectroscopy technology used in WasteLog®, critically important to ensure the quality and safety of compounded medications. We expect the offering to provide our customers with better control over their own compounding processes while increasing efficiency and saving external lab costs.”